UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy
in research participants with relapsed high risk MM [defined as gene expression profile (GEP)
70 gene score ≥0.66 and/or metaphase chromosomal abnormalities and/or high LDH ≥ 360U/L] by
establishing the (near) complete response rate. Response rate will be compared to case
matched historical controls (patients who relapsed on Total Therapy 2 or 3 with high-risk MM
defined as above). Disease-free survival and overall survival will be captured but are not
primary or secondary endpoints.